N-[(2S,3S,4R)-3,4-dihydroxy-16-methyl-1-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadecan-2-yl]tetracosanamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-[(2S,3S,4R)-3,4-dihydroxy-16-methyl-1-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadecan-2-yl]tetracosanamide
• 化学式: C₄₈H₉₅NO₉
• 分子量: 830.3
• InChiKey: QBJPYEAYFBSSDR-PIELMJAISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.7
• 重原子数：
  58
• 可旋转键数：
  41
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.98
• 拓扑面积：
  169
• 氢给体数：
  7
• 氢受体数：
  9

文献信息

• ACTIVATION OF INKT CELLS
  申请人：INSERM - Institut National de la Santé et de la Recherche Médicale

  公开号：EP2958595A1

  公开（公告）日：2015-12-30
• [EN] ACTIVATION OF INKT CELLS<br/>[FR] ACTIVATION DE CELLULES INKT
  申请人：INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE

  公开号：WO2014128225A1

  公开（公告）日：2014-08-28

  The present invention relates to particulate entity, such as a nanoparticle or conjugate, for use in particular as adjuvant in vaccine or immunotherapy. More specifically, the invention relates to a particulate entity comprising: iv. an iNKT cell agonist such as α Gal Car compound, and, v. one or more antigenic determinant(s) such as a tumour antigen(s) or pathogen-derived antigen(s), vi. a targeting agent that targets in vivo said iNKT cell agonist to dendritic cells, such as human BDCA3+ dendritic cells.